US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker ...
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
On Thursday, GSK plc (NYSE:GSK) revealed new preliminary data for Arexvy (Respiratory Syncytial Virus Vaccine, Adjuvanted) in ...
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will expand the number of people eligible for ...
FiercePharma7h
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
McKnight's Long-Term Care News21h
FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
BioSpace1d
Pfizer Wins FDA Approval of RSV Vaccine for Broader Adult Population
Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.
FiercePharma1d
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...
FDA Okays Pfizer's RSV Vaccine ABRYSVO For Adults Aged 18 To 59 At Increased Risk For Disease
Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration approved ABRYSVO (Respiratory Syncytial Virus Vaccine), the ...
biopharma-reporter12h
The FDA has approved Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59
The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...
pharmaphorum1d
Pfizer gets a leg up in RSV as FDA clears jab for all adults
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival ...